Does the media prefer ANGO or TMO?

In the previous week, Thermo Fisher Scientific had 91 more articles in the media than AngioDynamics. MarketBeat recorded 100 mentions for Thermo Fisher Scientific and 9 mentions for AngioDynamics. Thermo Fisher Scientific's average media sentiment score of 1.49 beat AngioDynamics' score of 1.40 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AngioDynamics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Thermo Fisher Scientific 90 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ANGO or WST?

In the previous week, West Pharmaceutical Services had 17 more articles in the media than AngioDynamics. MarketBeat recorded 26 mentions for West Pharmaceutical Services and 9 mentions for AngioDynamics. West Pharmaceutical Services' average media sentiment score of 1.63 beat AngioDynamics' score of 1.40 indicating that West Pharmaceutical Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AngioDynamics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive West Pharmaceutical Services 24 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer ANGO or BFLY?

In the previous week, AngioDynamics had 3 more articles in the media than Butterfly Network. MarketBeat recorded 9 mentions for AngioDynamics and 6 mentions for Butterfly Network. AngioDynamics' average media sentiment score of 1.40 beat Butterfly Network's score of 1.11 indicating that AngioDynamics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AngioDynamics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Butterfly Network 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ANGO or ATRC?

AtriCure has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AngioDynamics $320.17M 2.04 -$36.74M -$0.87 N/A AtriCure $534.53M 4.69 -$11.45M $0.21 234.62

Is ANGO or ATRC more profitable?

AtriCure has a net margin of 1.85% compared to AngioDynamics' net margin of -11.48%. AtriCure's return on equity of 2.34% beat AngioDynamics' return on equity. Company Net Margins Return on Equity Return on Assets AngioDynamics -11.48% -5.73% -3.77% AtriCure 1.85% 2.34% 1.77%

Does the media prefer ANGO or ATRC?

In the previous week, AtriCure had 10 more articles in the media than AngioDynamics. MarketBeat recorded 19 mentions for AtriCure and 9 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 1.40 beat AtriCure's score of 0.83 indicating that AngioDynamics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AngioDynamics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 9 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ESTA or ANGO?

In the previous week, AngioDynamics had 1 more articles in the media than Establishment Labs. MarketBeat recorded 9 mentions for AngioDynamics and 8 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.46 beat AngioDynamics' score of 1.40 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AngioDynamics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AngioDynamics (ANGO) Competitors

$15.78 +0.09 (+0.57%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$15.78 0.00 (0.00%)

As of 08/27/2026 07:30 PM Eastern

Compare

ANGO vs. TMO, WST, BFLY, ATRC, and ESTA

Should you buy AngioDynamics stock or one of its competitors? AngioDynamics's main competitors and comparable companies include Thermo Fisher Scientific (TMO), West Pharmaceutical Services (WST), Butterfly Network (BFLY), AtriCure (ATRC), and Establishment Labs (ESTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does AngioDynamics compare to Thermo Fisher Scientific?

AngioDynamics (NASDAQ:ANGO) and Thermo Fisher Scientific (NYSE:TMO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Thermo Fisher Scientific has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$320.17M	2.04	-$36.74M	-$0.87	N/A
Thermo Fisher Scientific	$46.34B	5.03	$6.70B	$18.59	33.92

AngioDynamics has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

In the previous week, Thermo Fisher Scientific had 91 more articles in the media than AngioDynamics. MarketBeat recorded 100 mentions for Thermo Fisher Scientific and 9 mentions for AngioDynamics. Thermo Fisher Scientific's average media sentiment score of 1.49 beat AngioDynamics' score of 1.40 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AngioDynamics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Thermo Fisher Scientific	90 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

AngioDynamics presently has a consensus price target of $19.50, indicating a potential upside of 23.57%. Thermo Fisher Scientific has a consensus price target of $619.41, indicating a potential downside of 1.78%. Given AngioDynamics' higher possible upside, equities research analysts clearly believe AngioDynamics is more favorable than Thermo Fisher Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
Thermo Fisher Scientific	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.78

Thermo Fisher Scientific has a net margin of 15.04% compared to AngioDynamics' net margin of -11.48%. Thermo Fisher Scientific's return on equity of 17.09% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-11.48%	-5.73%	-3.77%
Thermo Fisher Scientific	15.04%	17.09%	8.12%

89.4% of AngioDynamics shares are held by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are held by institutional investors. 6.0% of AngioDynamics shares are held by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Thermo Fisher Scientific beats AngioDynamics on 13 of the 16 factors compared between the two stocks.

How does AngioDynamics compare to West Pharmaceutical Services?

AngioDynamics (NASDAQ:ANGO) and West Pharmaceutical Services (NYSE:WST) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

AngioDynamics has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

AngioDynamics currently has a consensus target price of $19.50, indicating a potential upside of 23.57%. West Pharmaceutical Services has a consensus target price of $368.08, indicating a potential upside of 6.18%. Given AngioDynamics' higher probable upside, equities research analysts clearly believe AngioDynamics is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
West Pharmaceutical Services	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.87

West Pharmaceutical Services has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$320.17M	2.04	-$36.74M	-$0.87	N/A
West Pharmaceutical Services	$3.07B	7.94	$493.70M	$7.81	44.39

In the previous week, West Pharmaceutical Services had 17 more articles in the media than AngioDynamics. MarketBeat recorded 26 mentions for West Pharmaceutical Services and 9 mentions for AngioDynamics. West Pharmaceutical Services' average media sentiment score of 1.63 beat AngioDynamics' score of 1.40 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AngioDynamics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
West Pharmaceutical Services	24 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

West Pharmaceutical Services has a net margin of 16.98% compared to AngioDynamics' net margin of -11.48%. West Pharmaceutical Services' return on equity of 20.11% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-11.48%	-5.73%	-3.77%
West Pharmaceutical Services	16.98%	20.11%	14.83%

89.4% of AngioDynamics shares are held by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are held by institutional investors. 6.0% of AngioDynamics shares are held by company insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

West Pharmaceutical Services beats AngioDynamics on 14 of the 16 factors compared between the two stocks.

How does AngioDynamics compare to Butterfly Network?

AngioDynamics (NASDAQ:ANGO) and Butterfly Network (NYSE:BFLY) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, AngioDynamics had 3 more articles in the media than Butterfly Network. MarketBeat recorded 9 mentions for AngioDynamics and 6 mentions for Butterfly Network. AngioDynamics' average media sentiment score of 1.40 beat Butterfly Network's score of 1.11 indicating that AngioDynamics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AngioDynamics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Butterfly Network	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AngioDynamics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market.

AngioDynamics has a net margin of -11.48% compared to Butterfly Network's net margin of -66.74%. AngioDynamics' return on equity of -5.73% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-11.48%	-5.73%	-3.77%
Butterfly Network	-66.74%	-33.99%	-22.96%

AngioDynamics presently has a consensus price target of $19.50, indicating a potential upside of 23.57%. Butterfly Network has a consensus price target of $5.56, indicating a potential downside of 36.03%. Given AngioDynamics' higher probable upside, research analysts plainly believe AngioDynamics is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

89.4% of AngioDynamics shares are held by institutional investors. Comparatively, 37.9% of Butterfly Network shares are held by institutional investors. 6.0% of AngioDynamics shares are held by insiders. Comparatively, 22.0% of Butterfly Network shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

AngioDynamics has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$320.17M	2.04	-$36.74M	-$0.87	N/A
Butterfly Network	$97.61M	23.72	-$77.06M	-$0.29	N/A

Summary

AngioDynamics beats Butterfly Network on 11 of the 16 factors compared between the two stocks.

How does AngioDynamics compare to AtriCure?

AngioDynamics (NASDAQ:ANGO) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

In the previous week, AtriCure had 10 more articles in the media than AngioDynamics. MarketBeat recorded 19 mentions for AtriCure and 9 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 1.40 beat AtriCure's score of 0.83 indicating that AngioDynamics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AngioDynamics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	9 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

AngioDynamics currently has a consensus target price of $19.50, indicating a potential upside of 23.57%. AtriCure has a consensus target price of $49.89, indicating a potential upside of 1.26%. Given AngioDynamics' higher possible upside, analysts plainly believe AngioDynamics is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

AtriCure has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$320.17M	2.04	-$36.74M	-$0.87	N/A
AtriCure	$534.53M	4.69	-$11.45M	$0.21	234.62

AtriCure has a net margin of 1.85% compared to AngioDynamics' net margin of -11.48%. AtriCure's return on equity of 2.34% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-11.48%	-5.73%	-3.77%
AtriCure	1.85%	2.34%	1.77%

89.4% of AngioDynamics shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 6.0% of AngioDynamics shares are held by company insiders. Comparatively, 4.0% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

AngioDynamics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Summary

AtriCure beats AngioDynamics on 13 of the 16 factors compared between the two stocks.

How does AngioDynamics compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and AngioDynamics (NASDAQ:ANGO) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

AngioDynamics has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	10.14	-$51.06M	-$1.31	N/A
AngioDynamics	$320.17M	2.04	-$36.74M	-$0.87	N/A

Establishment Labs has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, AngioDynamics has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

In the previous week, AngioDynamics had 1 more articles in the media than Establishment Labs. MarketBeat recorded 9 mentions for AngioDynamics and 8 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.46 beat AngioDynamics' score of 1.40 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AngioDynamics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Establishment Labs currently has a consensus target price of $100.25, indicating a potential upside of 39.62%. AngioDynamics has a consensus target price of $19.50, indicating a potential upside of 23.57%. Given Establishment Labs' stronger consensus rating and higher possible upside, research analysts plainly believe Establishment Labs is more favorable than AngioDynamics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
AngioDynamics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 89.4% of AngioDynamics shares are held by institutional investors. 10.0% of Establishment Labs shares are held by insiders. Comparatively, 6.0% of AngioDynamics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

AngioDynamics has a net margin of -11.48% compared to Establishment Labs' net margin of -15.82%. AngioDynamics' return on equity of -5.73% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-15.82%	-196.69%	-10.73%
AngioDynamics	-11.48%	-5.73%	-3.77%

Summary

AngioDynamics beats Establishment Labs on 10 of the 17 factors compared between the two stocks.

Get AngioDynamics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANGO vs. The Competition

Export

Metric	AngioDynamics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$648.50M	$5.90B	$7.32B	$12.78B
Dividend Yield	N/A	1.75%	2.53%	11.03%
P/E Ratio	-18.14	25.97	271.29	25.71
Price / Sales	2.04	80.27	643.11	107.30
Price / Cash	50.15	33.01	79.17	53.57
Price / Book	3.82	6.20	13.01	6.26
Net Income	-$36.74M	$149.10M	$3.46B	$348.07M
7 Day Performance	0.19%	-0.15%	0.98%	0.47%
1 Month Performance	10.04%	7.53%	8.59%	5.19%
1 Year Performance	55.77%	6.19%	26.54%	16.68%

AngioDynamics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANGO AngioDynamics	3.3842 of 5 stars	$15.78 +0.6%	$19.50 +23.6%	+57.6%	$648.50M	$320.17M	N/A	760	Positive News
TMO Thermo Fisher Scientific	4.1829 of 5 stars	$587.51 +0.3%	$619.41 +5.4%	+29.1%	$216.96B	$44.56B	31.56	125,000	Trending News Insider Trade
WST West Pharmaceutical Services	4.3319 of 5 stars	$347.75 +0.3%	$368.08 +5.8%	+40.8%	$24.43B	$3.33B	44.44	10,800	News Coverage Positive News
BFLY Butterfly Network	1.5165 of 5 stars	$9.27 +2.7%	$5.56 -40.0%	+452.1%	$2.48B	$97.61M	N/A	460	Positive News
ATRC AtriCure	2.7087 of 5 stars	$45.71 +2.1%	$48.50 +6.1%	+32.1%	$2.32B	$534.53M	217.37	1,300	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANGO) was last updated on 8/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AngioDynamics (ANGO) Competitors

ANGO vs. TMO, WST, BFLY, ATRC, and ESTA

How does AngioDynamics compare to Thermo Fisher Scientific?

Summary

How does AngioDynamics compare to West Pharmaceutical Services?

Summary

How does AngioDynamics compare to Butterfly Network?

Summary

How does AngioDynamics compare to AtriCure?

Summary

How does AngioDynamics compare to Establishment Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANGO vs. The Competition

AngioDynamics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AngioDynamics (ANGO) Competitors

ANGO vs. TMO, WST, BFLY, ATRC, and ESTA

How does AngioDynamics compare to Thermo Fisher Scientific?

Which has stronger earnings and valuation, ANGO or TMO?

Which has more volatility & risk, ANGO or TMO?

Does the media prefer ANGO or TMO?

Do analysts recommend ANGO or TMO?

Is ANGO or TMO more profitable?

Do institutionals & insiders believe in ANGO or TMO?

Summary

How does AngioDynamics compare to West Pharmaceutical Services?

Which has more volatility & risk, ANGO or WST?

Do analysts rate ANGO or WST?

Which has stronger valuation & earnings, ANGO or WST?

Does the media refer more to ANGO or WST?

Is ANGO or WST more profitable?

Do institutionals and insiders believe in ANGO or WST?

Summary

How does AngioDynamics compare to Butterfly Network?

Does the media prefer ANGO or BFLY?

Which has more risk and volatility, ANGO or BFLY?

Is ANGO or BFLY more profitable?

Do analysts rate ANGO or BFLY?

Do insiders and institutionals believe in ANGO or BFLY?

Which has better earnings and valuation, ANGO or BFLY?

Summary

How does AngioDynamics compare to AtriCure?

Does the media prefer ANGO or ATRC?

Do analysts rate ANGO or ATRC?

Which has higher earnings & valuation, ANGO or ATRC?

Is ANGO or ATRC more profitable?

Do insiders & institutionals believe in ANGO or ATRC?

Which has more risk & volatility, ANGO or ATRC?

Summary

How does AngioDynamics compare to Establishment Labs?

Which has higher earnings & valuation, ESTA or ANGO?

Which has more volatility & risk, ESTA or ANGO?

Does the media refer more to ESTA or ANGO?

Do analysts recommend ESTA or ANGO?

Do insiders and institutionals hold more shares of ESTA or ANGO?

Is ESTA or ANGO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANGO vs. The Competition

AngioDynamics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools